



Docket No.: 66262-00002USPT

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yash P. Sharma

Serial No.: 09/474,677

Filed: December 29, 1999

For: Treatment and Prevention of HIV and Other

Viral Infections

Group Art Unit.: 1644

Examiner: Ronald B. Schwadron

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

04/05/2005 MBERHE 00000101 100447 09474677

01 FC:1806 18

180.00 DA

Dear Sir:

CERTIFICATE OF MAILING 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Missing Parts, P.O. Box 1450, Alexandria, VA 22313-1450

on March 31, 2005

Signature

In compliance with the duty of disclosure under 37 C.F.R. §1.56, it is respectfully requested that this be entered and the documents listed on attached Form PTO-SB08 be considered by the Examiner and made of record. Copies of the listed journal articles are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§1.97(g),(h), this Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

A fee as set forth in 37 C.F.R. §1.17(p) in the amount of \$180.00 is due. The Director is hereby authorized to deduct said fee from, Jenkens & Gilchrist, Deposit Account No. 10-0447 (66262-00002USPT), that the listed documents be made of record in the present case.

Serial No.: 09/474,677 Docket No.: 66262-00002USPT

Dated: March 31, 2005

Respectfully submitted,

Robert W. Busby, Jr.

Registration No.: 40,932

JENKENS & GILCHRIST, A PROFESSIONAL

CORPORATION

901 15th Street, Suite 900

Washington, DC 20005

(202) 326-1500

(202) 326-1555 (Fax)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
STATEMENT BY ADDITIONAL

Filing Date First Named Inventor Art Unit

Examiner Name

Application Number

09/474,677 December 29, 1999 Yash Sharma 1644

Ronald B. Schwadron, PhD

(Use as many sheets as necessary)

66262-00002USPT 3 1 of Sheet Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	Cite No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
	AA**	4,774,327	09-27-1988	Ogura et al.			
	AB**	5,459,031	10-17-1995	Blumen et al.			
	AC**	5,888,514	03-30-1999	Weisman			
	AD**	5,985,330	11-16-1999	Collin			
	AE**	6,143,533	11-07-2000	Sumi et al.			
	AF**	20020013368	01-31-2002	Collin et al.			
	AG**	20020176887	11-28-2002	Lord et al.			
	AH**	20030165480	09-04-2003	Zhu			
		20040039066	02-26-2001	Crea			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
		Muchmore, E.A., Chimpanzee models for human disease and immunobiology. Immunol Rev. 2001; 183:86-93.							
		Taiyeb-Ali, et al., Efficacy of 'Gamadent' toothpaste on the healing of gingival tissues, a preliminary report. J Oral Sci 2003; 45:153-159.							
		Buscher, H.P., et al., Biosynthesis of N-glycolylneuraminic acid in porcine submandibular glands. Subcellular site of hydroxylation of N-acetylneuraminic acid in the course of glycoprotein biosynthesis. Eur J Biochem. 1977; 77(2):297-310.							
		NIAID Anti-HIV Compound Lukor							
		CNN.com, Study: Stem cell lines contaminated, Jan. 23, 2005.							
		Muchmore, et al., Biosynthesis of N-Glycolyneuraminic Acid. J of Biol Chem 1989; 264(34):20216-20223.							
		Shaw and Schauer, The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. Biol Chem Hoppe Seyler 1988; 369(6):477-486.							
		Sumi, et al., Purification and identification of N-glycolylneuraminic acid (Neu5Gc) from the							
Examiner Signature		Date Considered							

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	09/474,677	
l IN	NFORMATIO	N DIS	SCLOSURE	Filing Date	December 29, 1999	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Yash Sharma	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	Ronald B. Schwadron, PhD	
Sheet	2	of	3	Attorney Docket Number	66262-00002USPT	

	Holothuroidea gumi, Cucumaria echinata. Prep Bioch and Biotech 2001; 31:135-146.
	McAuliffe, J., et al., Synthesis of O-glycolyl-linked neuraminic acids through a spirocyclic intermediate. Org Lett. 2002;4(18):3067-3069.
	Varki and Diaz, The release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups. Anal Biochem 1984; 137(1):236-247.
	Schauer and Wember, Hydroxylation and O-acetylation of N-acetylneuraminic acid bound to glycoproteins of isolated subcellular membranes from porcine and bovine submaxillary glands. Hoppe Seylers Z Physiol Chem. 1971; 352(10):1282- 1290.
	Chou, et al., A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A. 1998; 95(20): 11751-11756.
	Tangvoranuntakul, et al., Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A. 2003; 100(21): 12045-12050. published online before print October 1, 2003
	Suzuki K., The pattern of mammalian brain gangliosides. 3. Regional and developmental differences. J Neurochem. 1965;12(12):969-979.
	Suzuki K., The pattern of mammalian brain gangliosides. 2. Evaluation of the Extraction Procedures, Post-Mortem Changes and the Effect of Formalin Preservation. J Neurochem. 1965;12:629-638.
	Ledeen and Yu, Gangliosides: structure, isolation, and analysis. Methods Enzymol. 1982;83:139-191.
	Klein, et al., New sialic acids from biological sources identified by a comprehensive and sensitive approach: liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) of SIA quinoxalinones. Glycobiology. 1997;7(3):421-432.
	Letvin, N.L., Vaccines against human immunodeficiency virusprogress and prospects. N Engl J Med. 1993;329(19):1400-1405.
	Graham and Wright, Candidate AIDS vaccines. N Engl J Med. 1995;333(20):1331-1339.
1	Etemad-Moghadam, et al., Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol. 1999;73(10):8873-8879.
	Pantaleo and Fauci, Immunopathogenesis of HIV infection. Annu Rev Microbiol. 1996;50:825-854.
	Etemad-Moghadam, et al., Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J Virol. 1998;72(10):8437-8445.
	Zolla-Pazner, et al., Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol. 1998;72(2):1052-1059.
	Faillard and Blohm, [Synthesis of N-glycolyneuraminic acid]. Hoppe Seylers Z Physiol Chem. 1965;341(4):167-171. German.
	Meindl and Tuppy, Monatshefte fuer Chemie, 1969;100:1295-1306.
	Wirtz-Peitz, et al., [Synthesis of N-acyl-neuraminic acids from neuraminic acid-beta-methylglycoside. I]. Hoppe Seylers Z Physiol Chem. 1969;350(2):111-115. German.
	Sugata, et al., A Facile Preparation of the Methyl 2-Thioglycoside of N-Glycolylneuraminic Acid, An Efficient Donor of NeuGc. Tetrahedron Lett., 1996;37(15):2613-2614.
	Simeoni, et al., Synthesis of N -glycolylneuraminic Acid Ethylthioglycoside and Their Use as Glycosyl Donors. Russian Journal Of Bioorganic Chemistry, 1996;22:513 - 519.
	Chai, et al., Characterisation by mass spectrometry and 1H-NMR of novel hexasaccharides

Examiner	Date	
Signature	Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449A/B/PT	0		Complete if Known		
				Application Number	09/474,677	
11	NFORMATION	N DI	SCLOSURE	Filing Date	December 29, 1999	
S	TATEMENT I	BY /	APPLICANT	First Named Inventor	Yash Sharma	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	Ronald B. Schwadron, PhD	
Sheet	3	of	3	Attorney Docket Number	66262-00002USPT	

among the acidic O-linked carbohydrate chains of bovine submaxillary mucin. Eur J Biochem 1992;207:973-980.
Hummel and Schmidt, A versatile Synthesis of the lactoneo-Series antigens -Synthesis of the Sialyl Dimer Lewis X and Dimer Lewis Y. Tetrahedron Letters 1997;38:1173-1176.
Dwek, Glycobiology: Toward Understanding the Function of Sugars. Chem Rev. 1996;96(2):683-720.
Karkas and Chargaff. Studies on the Stability of Simple Derivatives of Sialic Acid. J Biol Chem. 1964;239:949-957.
Stamatos, et al., Desialylation of peripheral blood mononuclear cells promotes growth of HIV-1. Virology 1997;228(2):123-31.
Lepers, et al., A study on the regulation of N-glycoloylneuraminic acid biosynthesis and utilization in rat and mouse liver. Eur J Biochem. 1990;193(3):715-23.
Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie. 2001:83(7): 615-622.
Normile D. Comparative genomics. Gene expression differs in human and chimp brains. Science. 2001 Apr 6;292(5514):44-45.
Moreno E, et al. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology. 1998 Jul;8(7):695-705.
Varki A. Loss of N-glycolyneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. American Journal of Physical Anthropology. 2002;116(S33):54-69.
 Bardor, et al. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolyneuraminic acid into human cells. J. Biol. Chem. 2005 Feb;280(6):4228-4237
Tram, et al. Sialic acid content of infant saliva: comparison of breast fed with formula fed infants. Arch. Dis. Child. 1997:77:315-318.
Muchmore, et al. A structural difference between the cell surfaces of humans and great apes. Am. J. Phys. Anthropol. 1998 Oct;107(2):187-198.
Beaumont, et al. Increased Neutralization Sensitivity and Reduced Replicative capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees. Journal of Virology 2000;74(17):7699-7707.
www.herbshop.com/np_specl.htm Connect-All
 www.lifeplusvitamins.com/skin-care-beauty.htm Forever Young Tablets
 www.greenbarley.com/mercare.html Mer Care
 www.zooscape.com/cgi-bin/maitred/GreenCanyon/Questp405475 Joint Support
www.pnas.org/cgi/content/full/2131556100/DC1/7 Table 2. Sia and Neu5Gc content of common food items
www.seacucumber.cn/english/theory.asp
www.itmonline.org/arts/seacuke.htm
www.scienceblog.com/community/article1994.html
 www.hon.ch/News/HSN/515312.html
 www.health.ucsd.edu/news/2003/09_29_Varki.html
 www.msnbc.com/news/973366.asp?cp1=1
 www.easycart.net/cgi-bin/BeyondACenturyInc./search.cgi
www.casbellarmine.edu/tietjen/RootWeb/which_of_our_genes_make_us_human.htm

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered